Indianapolis-based Lilly will use Ambrx's protein-optimization technology, called ReCODE, in its efforts to develop biotech drugs. The two companies will try to bring to market drugs for treating metabolic diseases, central nervous system disorders and other conditions.
Lilly will pay Ambrx an initial upfront fee and make ongoing research support payments. Ambrx also may be compensated for reaching certain research and development milestones and, if products resulting from the collaboration are successfully commercialized, additional royalties.
Other terms of the deal were not disclosed. The collaboration builds on an earlier agreement between the companies signed in January.